Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

- PMLiVE

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

Avalere Health

- PMLiVE

Arcutis receives FDA approval for steroid-free plaque psoriasis treatment

Zoryve is the first and only PDE4 inhibitor approved for plaque psoriasis

- PMLiVE

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

Almirall shares positive topline results from atopic dermatitis trials

The company plans to submit a Marketing Authorisation Application to the EMA later this year

- PMLiVE

Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month

The global event will take place annually on 24 May to increase awareness of skin cancer

- PMLiVE

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

Galderma launches Rosacea Space to raise awareness

The platform invites people to share their experiences and what rosacea means to them

- PMLiVE

Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials

More than 50% of patients with moderate-to-severe atopic dermatitis experienced at least a 75% reduction in disease severity at 16 weeks

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links